| Symbol | URGN |
|---|---|
| Name | UROGEN PHARMA LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON, New Jersey, 08540, United States |
| Telephone | +1 646 768-9780 |
| Fax | — |
| — | |
| Website | https://www.urogen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001668243 |
| Description | UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Additional info from NASDAQ: |
2026-08-12 17:10
New Form SCHEDULE 13G/A - UroGen Pharma Ltd. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000947263-26-000072 <b>Size:</b> 10 KB
Read more
2026-07-29 12:00
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Read more
2026-06-24 14:03
Director Wildman Daniel George 🟢 acquired 18.0K shares (2 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021519
Read more
2026-06-24 14:02
Director Robinson James A. Jr. 🟢 acquired 18.0K shares (2 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021517
Read more
2026-06-24 14:01
Director Holden Stuart 🟢 acquired 20.0K shares (1 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021515
Read more
2026-06-24 14:00
Director BUTITTA CYNTHIA M 🟢 acquired 18.0K shares (2 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021513
Read more
2026-06-24 13:58
Director WEN LEANA 🟢 acquired 18.0K shares (2 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021511
Read more
2026-06-24 13:57
Director Belldegrun Arie 🟢 acquired 20.0K shares (1 derivative) of UroGen Pharma Ltd. (URGN) at $34.99 Transaction Date: Jun 22, 2026 | Filing ID: 021509
Read more
2026-06-22 19:53
📋 Schoenberg Mark (Officer) plans to sell 10K shares of UroGen Pharma Ltd. (at $35.01 each, total $350K) Filed: Jun 22, 2026 | ID: 000079
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05494411 | Named Patient Program for Mitomycin for Pyelocalyceal Solution | — | Urothelial Cancer of Renal Pelvis | Available | — | — | ClinicalTrials.gov |
| NCT02701023 | Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma | — | Urothelial Carcinoma Ureteral Location | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07725796 | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult… | Phase1 | Bladder (Urothelial, Transitional Cell) Cancer | Not_Yet_Recruiting | 2026-09-30 | 2029-08-02 | ClinicalTrials.gov |
| NCT07432659 | Add-On ZIDA Sock Therapy for Overactive Bladder | Na | Overactive Bladder | Recruiting | 2026-04-17 | 2028-03-01 | ClinicalTrials.gov |
| NCT06961383 | Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis | Phase2 | Secondary Progressive Multiple Sclerosis (SPMS) | Not_Yet_Recruiting | 2025-10-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT06774131 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Trac… | Phase3 | Upper Urinary Tract Urothelial Carcinoma | Recruiting | 2025-08-06 | 2028-03-01 | ClinicalTrials.gov |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediat… | Phase3 | Bladder Cancer | Active_Not_Recruiting | 2024-08-29 | 2026-09-01 | ClinicalTrials.gov |
| NCT06594926 | Working Out M0 Bipolar Androgen Therapy | Phase2 | Prostate Cancer | Recruiting | 2024-08-14 | 2028-12-31 | ClinicalTrials.gov |
| NCT06424275 | Prostate Cancer Awareness and Initiative for Screening in the European Union | — | Prostate Cancer | Enrolling_By_Invitation | 2024-06-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT06482138 | Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolec… | Na | Covid19 | Recruiting | 2024-01-24 | 2026-12-31 | ClinicalTrials.gov |
| NCT05874921 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Can… | — | Urothelial Carcinoma | Recruiting | 2023-11-17 | 2028-01-01 | ClinicalTrials.gov |
| NCT05898620 | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Phase3 | Rett Syndrome | Active_Not_Recruiting | 2023-06-13 | 2029-12-01 | ClinicalTrials.gov |
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuou… | Phase2 | Prostatic Neoplasms, Castration-Resistant | Recruiting | 2022-11-10 | 2027-11-10 | ClinicalTrials.gov |
| NCT04918810 | Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Pros… | Phase2 | Castration Resistant Prostatic Cancer | Terminated | 2022-07-29 | 2024-11-01 | ClinicalTrials.gov |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscl… | Phase1 | Non-muscle Invasive Bladder Cancer | Completed | 2022-06-01 | 2026-01-09 | ClinicalTrials.gov |
| NCT03309514 | Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease | Phase1 | Parkinson's Disease | Withdrawn | 2022-06-01 | 2024-06-30 | ClinicalTrials.gov |
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab … | Phase2 | Prostatic Neoplasms | Unknown | 2022-04-29 | 2024-12-01 | ClinicalTrials.gov |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-R… | Phase3 | Bladder Cancer | Active_Not_Recruiting | 2022-03-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT05228145 | Gene Therapy Study for Children With CLN5 Batten Disease | Phase1 | Neuronal Ceroid Lipofuscinosis CLN5 | Active_Not_Recruiting | 2022-01-31 | 2028-11-01 | ClinicalTrials.gov |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non… | Phase3 | Bladder Cancer | Completed | 2021-11-30 | 2023-02-02 | ClinicalTrials.gov |
| NCT04659629 | NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relap… | Phase1 | Solid Tumor | Completed | 2021-04-26 | 2024-08-15 | ClinicalTrials.gov |
| NCT04754737 | Antibiotic Usage Prior to OnabotulinumtoxinA Injection | Na | Antibiotic Stewardship | Recruiting | 2021-03-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive … | Phase3 | Bladder Cancer | Terminated | 2021-02-19 | 2023-03-17 | ClinicalTrials.gov |
| NCT06462001 | BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder … | Phase3 | Transitional Cell Carcinoma | Active_Not_Recruiting | 2020-12-10 | 2026-12-01 | ClinicalTrials.gov |
| NCT04856748 | Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tra… | — | Inflammation | Completed | 2020-09-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic … | Phase2 | Metastatic Castration-Resistant Prostate Cancer | Active_Not_Recruiting | 2020-08-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutet… | Phase2 | Metastatic Hormone Naive Prostate Cancer | Active_Not_Recruiting | 2020-04-21 | 2026-03-01 | ClinicalTrials.gov |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of t… | Phase3 | Prostate Cancer | Active_Not_Recruiting | 2020-03-31 | 2028-07-31 | ClinicalTrials.gov |
| NCT04346238 | Characterization of the Interruptions of the GAA Expansion and Study of Their I… | — | Friedreich Ataxia | Completed | 2020-03-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT04000763 | Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention | Na | Urinary Retention | Completed | 2019-12-20 | 2024-12-30 | ClinicalTrials.gov |
| NCT03910738 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Rel… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Recruiting | 2019-10-29 | 2027-12-01 | ClinicalTrials.gov |
| NCT04006691 | Efficacy and Safety of UGN-101 in Recurrent Patients | Phase3 | Carcinoma | Withdrawn | 2019-10-01 | 2020-03-31 | ClinicalTrials.gov |
| NCT03810508 | A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) | — | Charcot-Marie-Tooth Disease | Terminated | 2019-07-18 | 2022-02-15 | ClinicalTrials.gov |
| NCT03853876 | A Natural History Study of Aspartylglucosaminuria | — | Aspartylglucosaminuria | Terminated | 2019-04-18 | 2022-03-17 | ClinicalTrials.gov |
| NCT03685448 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) | Phase2 | Renal Cell Carcinoma | Completed | 2019-04-11 | 2025-06-04 | ClinicalTrials.gov |
| NCT03822650 | A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5) | — | Ceroid Lipofuscinosis, Neuronal 5 | Completed | 2019-03-13 | 2024-05-30 | ClinicalTrials.gov |
| NCT04063852 | PTNS on Urinary and Global Quality of Life in MS Patients | — | Multiple Sclerosis | Completed | 2019-02-27 | 2022-11-27 | ClinicalTrials.gov |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive… | Phase2 | Bladder Cancer | Completed | 2018-10-15 | 2020-10-21 | ClinicalTrials.gov |
| NCT03508921 | Comparison of Methods for Prevention of Urinary Tract Infection Following Botox… | Phase4 | Overactive Bladder | Terminated | 2018-07-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastat… | Phase2 | Cancer of the Prostate | Completed | 2018-01-29 | 2021-12-31 | ClinicalTrials.gov |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | Phase2 | Renal Cell Carcinoma, Clear Cell | Unknown | 2017-12-12 | 2023-06-04 | ClinicalTrials.gov |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination… | Phase2 | Renal Cell Carcinoma | Unknown | 2017-10-19 | 2022-12-31 | ClinicalTrials.gov |
| NCT02662062 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder C… | Phase2 | Bladder Cancer | Completed | 2017-07-11 | 2024-08-26 | ClinicalTrials.gov |
| NCT03493997 | Multicentre International STudy for the Prevention With Ialuril® of Radio-induc… | Phase2 | Prostate Cancer | Completed | 2017-04-04 | 2020-05-31 | ClinicalTrials.gov |
| NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | Phase3 | Carcinoma, Transitional Cell | Completed | 2017-04-04 | 2020-03-05 | ClinicalTrials.gov |
| NCT02674269 | Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Rele… | Phase1 | Overactive Bladder | Withdrawn | 2016-10-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT03091764 | Evaluation of a Patient-Reported Symptom Index for NMIBC | — | Superficial Bladder Cancer | Completed | 2016-07-01 | 2021-08-30 | ClinicalTrials.gov |
| NCT02537938 | Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple A… | Phase1 | Alzheimer's Disease | Completed | 2016-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02604225 | Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Disc… | Phase3 | Cancer | Completed | 2015-12-01 | 2019-12-30 | ClinicalTrials.gov |
| NCT02534480 | Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-asce… | Phase1 | Alzheimer's Disease | Completed | 2015-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02307487 | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel a… | Phase2 | Bladder Cancer | Completed | 2014-12-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02315560 | Foot Neuromodulation for Nocturnal Enuresis | Na | Bedwetting | Completed | 2014-09-01 | 2017-04-06 | ClinicalTrials.gov |
| NCT02179099 | Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients | Phase1 | Overactive Bladder | Terminated | 2014-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02033993 | Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or Af… | Phase2 | Urothelial Cancer | Completed | 2014-03-11 | 2020-10-28 | ClinicalTrials.gov |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Ri… | Phase3 | Prostatic Neoplasms | Active_Not_Recruiting | 2014-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate… | Phase3 | Prostatic Neoplasms | Active_Not_Recruiting | 2014-03-01 | 2027-06-30 | ClinicalTrials.gov |
| NCT02582697 | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Po… | Phase3 | Germ Cell Tumor | Recruiting | 2014-02-01 | 2029-12-31 | ClinicalTrials.gov |
| NCT02016118 | Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tra… | — | Recurrent Urinary Tract Infections | Unknown | 2014-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01997983 | Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Ge… | Phase1 | Interstitial Cystitis | Completed | 2013-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02091596 | Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers | Phase2 | Diabetic Foot Ulcer | Completed | 2013-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02119754 | Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers | Phase2 | Diabetic Foot Ulcer | Completed | 2013-10-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02241395 | Cell Therapy as Treatment for Cerebral Palsy | Phase1 | Cerebral Palsy | Withdrawn | 2013-08-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02948543 | Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Musc… | Phase3 | Bladder Cancer | Unknown | 2013-07-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT01803295 | Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC | Na | Carcinoma of Urinary Bladder, Superficial | Completed | 2013-06-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01799499 | A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect o… | Na | Non Muscle Invasive Bladder Cancer | Withdrawn | 2013-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT02891460 | Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3)… | Na | Urinary Bladder Neoplasms | Completed | 2013-01-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02009124 | Stem Cell Therapy in Spinal Cord Injury | Phase2 | Spinal Cord Injury | Withdrawn | 2012-08-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01648010 | Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mit… | Na | Carcinoma of Urinary Bladder, Invasive | Completed | 2011-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01329926 | Molecular Analysis of Human Neural Stem Cells | — | Parkinson's Disease | Withdrawn | 2011-06-30 | 2023-12-31 | ClinicalTrials.gov |
| NCT02245711 | Cell Therapy in Limb Girdle Muscular Dystrophy | Phase1 | Limb Girdle Muscular Dystrophy | Withdrawn | 2010-12-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01978821 | Stem Cell Therapy for Cerebral Palsy | Phase1 | Cerebral Palsy | Withdrawn | 2010-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT02028104 | Stem Cell Therapy in Traumatic Brain Injury | Phase1 | Traumatic Brain Injury | Withdrawn | 2010-01-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01974973 | Stem Cell Therapy in Autism Spectrum Disorders | Phase1 | Autism Spectrum Disorders | Withdrawn | 2009-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01264471 | Mechanisms of Mitochondrial Defects in Gulf War Syndrome | — | Gulf War Syndrome | Completed | 2009-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00860652 | Radiotherapy - Adjuvant Versus Early Salvage | Na | Prostate Cancer | Active_Not_Recruiting | 2009-03-03 | 2026-12-01 | ClinicalTrials.gov |
| NCT00834327 | Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome | Phase2 | Restless Legs Syndrome | Terminated | 2009-02-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT02241434 | Stem Cell Therapy in Duchenne Muscular Dystrophy | Phase1 | Duchenne Muscular Dystrophy | Withdrawn | 2009-01-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02245776 | Stem Cell Therapy in Incurable Neurological Disorders | Phase1 | Neurological; Disorder, Nervous System | Withdrawn | 2008-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02050776 | Stem Cell Therapy in Limb Girdle Muscular Dystrophy | Phase1 | Limb Girdle Muscular Dystrophy | Withdrawn | 2008-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT02027246 | Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury | Phase1 | Spinal Cord Injury | Withdrawn | 2008-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00809302 | Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease | Phase2 | Early Parkinson Disease | Terminated | 2008-12-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT02065778 | Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke | Phase1 | Cerebrovascular Accident | Withdrawn | 2008-12-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01984814 | Stem Cell Therapy for Amyotrophic Lateral Sclerosis | Phase2 | Amyotrophic Lateral Sclerosis | Withdrawn | 2008-12-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT02245698 | Autologous Stem Cell Therapy in Stroke | Phase1 | Stroke | Withdrawn | 2008-12-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02242071 | Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis | Phase1 | Amyotrophic Lateral Sclerosis | Withdrawn | 2008-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT00683436 | Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primar… | Phase2 | Primary Insomnia | Terminated | 2008-05-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00221676 | Effectiveness of Influenza Vaccination Among General Practitioners | Phase4 | Influenza | Completed | 2002-07-01 | 2004-06-01 | ClinicalTrials.gov |
Total clinical trials: 87
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| UGN-501 | Other | Phase PHASE1 | Bladder (Urothelial, Transitional Cell) Cancer | NOT_YET_RECRUITING | NCT07725796 |
| Enzalutamide | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04419402 |
| Lu-PSMA | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04419402 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| NGN-401 | Other | Phase PHASE3 | Rett Syndrome | ACTIVE_NOT_RECRUITING | NCT05898620 |
| Reuse of existing data from patients' medical records | Other | Preclinical | Friedreich Ataxia | COMPLETED | NCT04346238 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| PluroGel | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| PluroGel N | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| PluroGel | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| PluroGel N | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Biopsy and Cytobrush | Other | Approved | Covid19 | RECRUITING | NCT06482138 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| UGN-102 | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT03558503 |
| Pembrolizumab plus denosumab | Other | Phase PHASE2 | Renal Cell Carcinoma, Clear Cell | UNKNOWN | NCT03280667 |
| Pembrolizumab plus denosumab | Other | Phase PHASE2 | Renal Cell Carcinoma, Clear Cell | UNKNOWN | NCT03280667 |
| Pembrolizumab plus denosumab | Other | Phase PHASE2 | Renal Cell Carcinoma, Clear Cell | UNKNOWN | NCT03280667 |
| Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | COMPLETED | NCT02033993 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | COMPLETED | NCT02033993 |
| Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | COMPLETED | NCT02033993 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Urothelial Cancer | COMPLETED | NCT02033993 |
| LHRHA or Surgical Castration | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446405 |
| NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446405 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446405 |
| Assessment of disability | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| MRI | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Placebo 4 mL Solution for Injection | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Assessment of disability | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| MRI | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Placebo 4 mL Solution for Injection | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | RECRUITING | NCT03910738 |
| Alfarix | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00221676 |
| Alfarix | Other | Phase PHASE4 | Influenza | COMPLETED | NCT00221676 |
| Ambien CR | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Placebo | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Adipiplon | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Ambien CR | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Placebo | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Adipiplon | Other | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| aplindore MR tablets or Placebo | Other | Phase PHASE2 | Early Parkinson Disease | TERMINATED | NCT00809302 |
| aplindore MR tablets or Placebo | Other | Phase PHASE2 | Early Parkinson Disease | TERMINATED | NCT00809302 |
| aplindore MR tablets or Placebo | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT00834327 |
| aplindore MR tablets or Placebo | Other | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT00834327 |
| TC-3 gel mixed with Mitomycin C (MMC) | Other | Approved | Carcinoma of Urinary Bladder, Invasive | COMPLETED | NCT01648010 |
| TC-3 gel | Other | Approved | Carcinoma of Urinary Bladder, Invasive | COMPLETED | NCT01648010 |
| Ialuril | Other | Preclinical | Recurrent Urinary Tract Infections | UNKNOWN | NCT02016118 |
| Ialuril | Other | Preclinical | Recurrent Urinary Tract Infections | UNKNOWN | NCT02016118 |
| Plurogel PN | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02119754 |
| Plurogel PN | Other | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02119754 |
| Blood Collection | Other | Preclinical | Gulf War Syndrome | COMPLETED | NCT01264471 |
| Skin biopsy | Other | Preclinical | Gulf War Syndrome | COMPLETED | NCT01264471 |
| Blood Collection | Other | Preclinical | Gulf War Syndrome | COMPLETED | NCT01264471 |
| Skin biopsy | Other | Preclinical | Gulf War Syndrome | COMPLETED | NCT01264471 |
| TC-3 hydrogel | Other | Approved | Non Muscle Invasive Bladder Cancer | WITHDRAWN | NCT01799499 |
| NGP 555 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02534480 |
| NGP 555 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02534480 |
| BTX mixed with TC-3 Gel | Other | Phase PHASE1 | Overactive Bladder | TERMINATED | NCT02179099 |
| TC-3 Gel mixed with Botox (BTX) | Other | Phase PHASE1 | Interstitial Cystitis | COMPLETED | NCT01997983 |
| 80 mg MMC in 40 mL TC-3. | Other | Approved | Urinary Bladder Neoplasms | COMPLETED | NCT02891460 |
| 40 mg MMC in 40 mL TC-3. | Other | Approved | Urinary Bladder Neoplasms | COMPLETED | NCT02891460 |
| NGP 555 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02537938 |
| NGP 555 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02537938 |
| TC-3 Gel | Other | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| 400 IU of BotuGelTM (60ml) | Other | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| 300 IU of BotuGelTM (60ml) | Other | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| 160 mg MMC in 60ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 140 mg MMC in 60ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 120 mg MMC in 60ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 160 mg MMC in 90ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 140 mg MMC in 90ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 120 mg MMC in 90ml gel | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 80 mg MMC gel | Other | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| Standard of care MMC mixed with water | Other | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| 40 mg MMC gel | Other | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| MitoGel | Other | Preclinical | Urothelial Carcinoma Ureteral Location | NO_LONGER_AVAILABLE | NCT02701023 |
| TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS | Other | Approved | Bedwetting | COMPLETED | NCT02315560 |
| TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS | Other | Approved | Bedwetting | COMPLETED | NCT02315560 |
| Stem Cell | Other | Phase PHASE1 | Neurological; Disorder, Nervous System | WITHDRAWN | NCT02245776 |
| Stem Cell | Other | Phase PHASE1 | Neurological; Disorder, Nervous System | WITHDRAWN | NCT02245776 |
| Stem Cell | Other | Phase PHASE1 | Neurological; Disorder, Nervous System | WITHDRAWN | NCT02245776 |
| Stem Cell | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | WITHDRAWN | NCT02245711 |
| Stem Cell | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | WITHDRAWN | NCT02245711 |
| Stem cell | Other | Phase PHASE1 | Stroke | WITHDRAWN | NCT02245698 |
| Stem cell | Other | Phase PHASE1 | Stroke | WITHDRAWN | NCT02245698 |
| Stem Cell | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | WITHDRAWN | NCT02242071 |
| Stem Cell | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | WITHDRAWN | NCT02242071 |
| Stem Cell | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | WITHDRAWN | NCT02241434 |
| Stem Cell | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | WITHDRAWN | NCT02241434 |
| Intrathecal autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebral Palsy | WITHDRAWN | NCT02241395 |
| Intrathecal autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebral Palsy | WITHDRAWN | NCT02241395 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebrovascular Accident | WITHDRAWN | NCT02065778 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebrovascular Accident | WITHDRAWN | NCT02065778 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | WITHDRAWN | NCT02050776 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Limb Girdle Muscular Dystrophy | WITHDRAWN | NCT02050776 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Traumatic Brain Injury | WITHDRAWN | NCT02028104 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Traumatic Brain Injury | WITHDRAWN | NCT02028104 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Spinal Cord Injury | WITHDRAWN | NCT02027246 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Spinal Cord Injury | WITHDRAWN | NCT02027246 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE2 | Spinal Cord Injury | WITHDRAWN | NCT02009124 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE2 | Spinal Cord Injury | WITHDRAWN | NCT02009124 |
| Stem cell | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | WITHDRAWN | NCT01984814 |
| Stem cell | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | WITHDRAWN | NCT01984814 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebral Palsy | WITHDRAWN | NCT01978821 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Cerebral Palsy | WITHDRAWN | NCT01978821 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Autism Spectrum Disorders | WITHDRAWN | NCT01974973 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Autism Spectrum Disorders | WITHDRAWN | NCT01974973 |
| Autologous bone marrow mononuclear cell transplantation | Other | Phase PHASE1 | Autism Spectrum Disorders | WITHDRAWN | NCT01974973 |
| Reuse of existing data from patients' medical records | Other | Preclinical | Friedreich Ataxia | UNKNOWN | NCT04346238 |
| Reuse of existing data from patients' medical records | Other | Preclinical | Friedreich Ataxia | UNKNOWN | NCT04346238 |
| UGN-101 instillations | Other | Phase PHASE3 | Carcinoma | WITHDRAWN | NCT04006691 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT02604225 |
| Methoxyflurane | Other | Phase PHASE3 | Cancer | COMPLETED | NCT02604225 |
| Placebo | Other | Phase PHASE3 | Cancer | COMPLETED | NCT02604225 |
| Methoxyflurane | Other | Phase PHASE3 | Cancer | COMPLETED | NCT02604225 |
| Radiotherapy only | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| Radiotherapy+IAluril®+Ialuril Soft Gels® | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| Radiotherapy only | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| Radiotherapy+IAluril®+Ialuril Soft Gels® | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| Radiotherapy only | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| Radiotherapy+IAluril®+Ialuril Soft Gels® | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT03493997 |
| UGN-101 instillations | Other | Phase PHASE3 | Carcinoma, Transitional Cell | COMPLETED | NCT02793128 |
| Ipilimumab | Other | Phase PHASE2 | Renal Cell Carcinoma | UNKNOWN | NCT03177239 |
| Nivolumab | Other | Phase PHASE2 | Renal Cell Carcinoma | UNKNOWN | NCT03177239 |
| Intracerebral microinjections | Other | Phase PHASE1 | Parkinson's Disease | WITHDRAWN | NCT03309514 |
| Intracerebral microinjections | Other | Phase PHASE1 | Parkinson's Disease | WITHDRAWN | NCT03309514 |
| Intracerebral microinjections | Other | Phase PHASE1 | Parkinson's Disease | WITHDRAWN | NCT03309514 |
| Harvesting of neural stem cells | Other | Preclinical | Parkinson's Disease | WITHDRAWN | NCT01329926 |
| Harvesting of neural stem cells | Other | Preclinical | Parkinson's Disease | WITHDRAWN | NCT01329926 |
| Harvesting of neural stem cells | Other | Preclinical | Parkinson's Disease | WITHDRAWN | NCT01329926 |
| Cabazitaxel | Other | Phase PHASE2 | Cancer of the Prostate | COMPLETED | NCT03392428 |
| 177Lu-PSMA617 | Other | Phase PHASE2 | Cancer of the Prostate | COMPLETED | NCT03392428 |
| Cabazitaxel | Other | Phase PHASE2 | Cancer of the Prostate | COMPLETED | NCT03392428 |
| 177Lu-PSMA617 | Other | Phase PHASE2 | Cancer of the Prostate | COMPLETED | NCT03392428 |
| Early Salvage Radiotherapy | Drug | Approved | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT00860652 |
| Adjuvant Radiotherapy | Drug | Approved | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT00860652 |
| Early Salvage Radiotherapy | Drug | Approved | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT00860652 |
| Adjuvant Radiotherapy | Drug | Approved | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT00860652 |
| Mitomycin (MM) | Other | Phase PHASE3 | Bladder Cancer | UNKNOWN | NCT02948543 |
| Bacillus of Calmette-Guerin (BCG) | Other | Phase PHASE3 | Bladder Cancer | UNKNOWN | NCT02948543 |
| Mitomycin (MM) | Other | Phase PHASE3 | Bladder Cancer | UNKNOWN | NCT02948543 |
| Bacillus of Calmette-Guerin (BCG) | Other | Phase PHASE3 | Bladder Cancer | UNKNOWN | NCT02948543 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| External Beam Radiotherapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Luteinizing Hormone-Releasing Hormone Analog | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Placebo oral tablet | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Darolutamide | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04136353 |
| Injection of OnabotulinumtoxinA (BTX-A) | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Extended Antibiotics | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Periprocedural Antibiotics | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Injection of OnabotulinumtoxinA (BTX-A) | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Extended Antibiotics | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Periprocedural Antibiotics | Other | Phase PHASE4 | Overactive Bladder | TERMINATED | NCT03508921 |
| Nivolumab | Other | Phase PHASE2 | Prostatic Neoplasms | UNKNOWN | NCT05150236 |
| Ipilimumab | Other | Phase PHASE2 | Prostatic Neoplasms | UNKNOWN | NCT05150236 |
| 177Lu-PSMA-617 | Other | Phase PHASE2 | Prostatic Neoplasms | UNKNOWN | NCT05150236 |
| Enzalutamide | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | UNKNOWN | NCT04419402 |
| Lu-PSMA | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | UNKNOWN | NCT04419402 |
| cystoscopic injection of onabotulinumtoxinA | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| Prophylactic antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| No antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| cystoscopic injection of onabotulinumtoxinA | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| Prophylactic antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| No antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| cystoscopic injection of onabotulinumtoxinA | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| Prophylactic antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| No antibiotic | Other | Approved | Antibiotic Stewardship | RECRUITING | NCT04754737 |
| TURBT | Other | Phase PHASE3 | Bladder Cancer | TERMINATED | NCT04688931 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | TERMINATED | NCT04688931 |
| Mitomycin | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| Bacillus Calmette-Guerin Vaccine Intravesical | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| Mitomycin | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| Bacillus Calmette-Guerin Vaccine Intravesical | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| Mitomycin | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| Bacillus Calmette-Guerin Vaccine Intravesical | Other | Phase PHASE3 | Transitional Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06462001 |
| NGN-101 | Other | Phase PHASE1 | Neuronal Ceroid Lipofuscinosis CLN5 | ACTIVE_NOT_RECRUITING | NCT05228145 |
| NGN-101 | Other | Phase PHASE1 | Neuronal Ceroid Lipofuscinosis CLN5 | ACTIVE_NOT_RECRUITING | NCT05228145 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | COMPLETED | NCT05136898 |
| Pembrolizumab Injection [Keytruda] | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| NL-201 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| Pembrolizumab Injection [Keytruda] | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| NL-201 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| UGN-102 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| Docetaxel intermittent | Other | Phase PHASE2 | Castration Resistant Prostatic Cancer | TERMINATED | NCT04918810 |
| Docetaxel intermittent | Other | Phase PHASE2 | Castration Resistant Prostatic Cancer | TERMINATED | NCT04918810 |
| Enzalutamide | Other | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Abiraterone acetate | Other | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Patient-specific adaptive therapy | Drug | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Enzalutamide | Other | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Abiraterone acetate | Other | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Patient-specific adaptive therapy | Drug | Phase PHASE2 | Prostatic Neoplasms, Castration-Resistant | RECRUITING | NCT05393791 |
| Radiotherapy | Drug | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Cisplatin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Pembrolizumab | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Radiotherapy | Drug | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Cisplatin | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Pembrolizumab | Other | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02662062 |
| Jelmyto (mitomycin) for pyelocalyceal solution | Other | Preclinical | Urothelial Carcinoma | RECRUITING | NCT05874921 |
| Mitomycin for pyelocalyceal solution | Other | Preclinical | Urothelial Cancer of Renal Pelvis | AVAILABLE | NCT05494411 |
| superficial peroneal nerve stimulation | Other | Approved | Urinary Retention | COMPLETED | NCT04000763 |
| superficial peroneal nerve stimulation | Other | Approved | Urinary Retention | COMPLETED | NCT04000763 |
| Sodium Chloride 0.9% | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| NG01 - Autologous bone marrow derived human stromal cells | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| Sodium Chloride 0.9% | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| NG01 - Autologous bone marrow derived human stromal cells | Other | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | Drug | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Enzalutamide | Other | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Filgrastim | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Pegylated G-CSF (Pegfilgrastim) | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Cisplatin | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Etoposide | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Bleomycin (active name: Bleomycin Sulfate) | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Filgrastim | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Pegylated G-CSF (Pegfilgrastim) | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Cisplatin | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Etoposide | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Bleomycin (active name: Bleomycin Sulfate) | Other | Phase PHASE3 | Germ Cell Tumor | RECRUITING | NCT02582697 |
| Docetaxel | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| 177Lu-PSMA-617 | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| Docetaxel | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| 177Lu-PSMA-617 | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| Docetaxel | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| 177Lu-PSMA-617 | Other | Phase PHASE2 | Metastatic Hormone Naive Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04343885 |
| Cabozantinib | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT03685448 |
| Cabozantinib | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT03685448 |
| Risk-based screening algorithm | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT06424275 |
| Risk-based screening algorithm | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT06424275 |
| Risk-based screening algorithm | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT06424275 |
| Gemcitabine | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| UGN-201 | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| UGN-301 | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| UGN-103 | Other | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06331299 |
| ZIDA Control Sock | Other | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| NGN-401 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT05898620 |
| NGN-401 | Other | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT05898620 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-104 | Other | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| Testosterone Enanthate | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06594926 |
| ZIDA Control Sock | DEVICE | Approved | Overactive Bladder | RECRUITING | NCT07432659 |
| Sodium Chloride 0.9% | OTHER | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| NG01 - Autologous bone marrow derived human stromal cells | BIOLOGICAL | Phase PHASE2 | Secondary Progressive Multiple Sclerosis (SPMS) | NOT_YET_RECRUITING | NCT06961383 |
| UGN-104 | DRUG | Phase PHASE3 | Upper Urinary Tract Urothelial Carcinoma | RECRUITING | NCT06774131 |
| UGN-103 | DRUG | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06331299 |
| NGN-401 | GENETIC | Phase PHASE3 | Rett Syndrome | RECRUITING | NCT05898620 |
| Jelmyto (mitomycin) for pyelocalyceal solution | DRUG | Preclinical | Urothelial Carcinoma | RECRUITING | NCT05874921 |
| Mitomycin for pyelocalyceal solution | DRUG | Preclinical | Urothelial Cancer of Renal Pelvis | AVAILABLE | NCT05494411 |
| Gemcitabine | DRUG | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| UGN-201 | DRUG | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| UGN-301 | DRUG | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05375903 |
| NGN-101 | GENETIC | Phase PHASE1 | Neuronal Ceroid Lipofuscinosis CLN5 | ACTIVE_NOT_RECRUITING | NCT05228145 |
| 177Lu-PSMA-617 | DRUG | Phase PHASE2 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT05150236 |
| TURBT | PROCEDURE | Phase PHASE3 | Bladder Cancer | TERMINATED | NCT04688931 |
| Pembrolizumab Injection [Keytruda] | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| NL-201 | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04659629 |
| Lu-PSMA | DRUG | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04419402 |
| UGN-102 | DRUG | Phase PHASE3 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05243550 |
| Pembrolizumab plus denosumab | DRUG | Phase PHASE2 | Renal Cell Carcinoma, Clear Cell | UNKNOWN | NCT03280667 |
| Ipilimumab | DRUG | Phase PHASE2 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT05150236 |
| Nivolumab | DRUG | Phase PHASE2 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT05150236 |
| 80 mg MMC in 40 mL TC-3. | DEVICE | Approved | Urinary Bladder Neoplasms | COMPLETED | NCT02891460 |
| 40 mg MMC in 40 mL TC-3. | DEVICE | Approved | Urinary Bladder Neoplasms | COMPLETED | NCT02891460 |
| UGN-101 instillations | DRUG | Phase PHASE3 | Carcinoma | WITHDRAWN | NCT04006691 |
| MitoGel | DRUG | Preclinical | Urothelial Carcinoma Ureteral Location | NO_LONGER_AVAILABLE | NCT02701023 |
| TC-3 Gel | DEVICE | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| 400 IU of BotuGelTM (60ml) | DRUG | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| 300 IU of BotuGelTM (60ml) | DRUG | Phase PHASE1 | Overactive Bladder | WITHDRAWN | NCT02674269 |
| NGP 555 | DRUG | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02537938 |
| External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | RADIATION | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| Conventional NSAA | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446444 |
| LHRHA or Surgical Castration | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446405 |
| NSAA | DRUG | Phase PHASE3 | Prostatic Neoplasms | ACTIVE_NOT_RECRUITING | NCT02446405 |
| Enzalutamide | DRUG | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04419402 |
| 160 mg MMC in 60ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 140 mg MMC in 60ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 120 mg MMC in 60ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 160 mg MMC in 90ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 140 mg MMC in 90ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| 120 mg MMC in 90ml gel | DRUG | Phase PHASE2 | Bladder Cancer | COMPLETED | NCT02307487 |
| Plurogel PN | DRUG | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02119754 |
| PluroGel | DRUG | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| PluroGel N | DRUG | Phase PHASE2 | Diabetic Foot Ulcer | COMPLETED | NCT02091596 |
| 80 mg MMC gel | DEVICE | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| Standard of care MMC mixed with water | OTHER | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| 40 mg MMC gel | DEVICE | Approved | Carcinoma of Urinary Bladder, Superficial | COMPLETED | NCT01803295 |
| aplindore MR tablets or Placebo | DRUG | Phase PHASE2 | Restless Legs Syndrome | TERMINATED | NCT00834327 |
| Ambien CR | DRUG | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Placebo | DRUG | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| Adipiplon | DRUG | Phase PHASE2 | Primary Insomnia | TERMINATED | NCT00683436 |
| BTX mixed with TC-3 Gel | DEVICE | Phase PHASE1 | Overactive Bladder | TERMINATED | NCT02179099 |
| TC-3 Gel mixed with Botox (BTX) | DEVICE | Phase PHASE1 | Interstitial Cystitis | COMPLETED | NCT01997983 |
| TC-3 hydrogel | DEVICE | Approved | Non Muscle Invasive Bladder Cancer | WITHDRAWN | NCT01799499 |
| TC-3 gel mixed with Mitomycin C (MMC) | DEVICE | Approved | Carcinoma of Urinary Bladder, Invasive | COMPLETED | NCT01648010 |
| TC-3 gel | DEVICE | Approved | Carcinoma of Urinary Bladder, Invasive | COMPLETED | NCT01648010 |
Total products: 413